Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic
Isoniazid is an efficacious treatment for latent tuberculosis. Concerns remain, however, regarding hepatotoxicity associated with this medication. In addition, adherence may be suboptimal because at least 6 months of treatment is required. We extracted information from our latent tuberculosis treatm...
Gespeichert in:
| Veröffentlicht in: | American journal of respiratory and critical care medicine 2003-08, Vol.168 (4), p.443-447 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 447 |
|---|---|
| container_issue | 4 |
| container_start_page | 443 |
| container_title | American journal of respiratory and critical care medicine |
| container_volume | 168 |
| creator | LoBue, Philip A Moser, Kathleen S |
| description | Isoniazid is an efficacious treatment for latent tuberculosis. Concerns remain, however, regarding hepatotoxicity associated with this medication. In addition, adherence may be suboptimal because at least 6 months of treatment is required. We extracted information from our latent tuberculosis treatment database to determine adverse effects and treatment completion rates associated with the use of isoniazid at a county tuberculosis clinic. Outcomes were available for 3,788 patients started on isoniazid between 1999 and 2002. Six hundred seventy-two patients (18%) experienced one or more adverse effects, including 10 (0.3%) determined to have isoniazid-associated liver injury. No hospitalizations or deaths occurred in patients experiencing an adverse effect. A higher incidence of adverse effects was associated with increasing age. Sixty-four percent of patients completed at least 6 months of isoniazid. Higher completion rates were associated with younger age, Hispanic ethnicity, and non-U.S. country of birth. Lower completion rates were associated with being homelessness, using excess alcohol, and having experienced an adverse effect. In summary, we conclude that in our clinic population isoniazid is a safe therapy for latent tuberculosis, but its effectiveness is limited by modest completion rates. |
| doi_str_mv | 10.1164/rccm.200303-390OC |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_199561155</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>389399981</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-73f802e896472c951af0a5d6639ba6c88fa47247f905083bd1df4e9e7078b21a3</originalsourceid><addsrcrecordid>eNpFkE1LAzEQhoMotlZ_gBcJ3jxszWyS3c1RitrCQj204C1ks4lN2Y-a7CL66926BU8zMM-8MzwI3QKZAyTs0Wtdz2NCKKERFWS9OENT4JRHTKTkfOhJSiPGxPsEXYWwJwTiDMglmkCcsiTmfIrybTC4tXgV2sapH1di23qcq840Hd70hfG6r9rgAl411ujOtQ12DVb4rS8qp_HSqKrb4UXlGqev0YVVVTA3pzpD25fnzWIZ5evX1eIpj_TwTBel1GYkNplIWBprwUFZoniZJFQUKtFZZtUwYKkVhJOMFiWUlhlhUpJmRQyKztD9mHvw7WdvQif3be-b4aQEIXgCwPkAwQhp34bgjZUH72rlvyUQedQnj_rkqE_-6Rt27k7BfVGb8n_j5GsAHkZg5z52X84bGWpVVQMOUu2PgZBkkknGKP0FJ6540g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199561155</pqid></control><display><type>article</type><title>Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><source>American Thoracic Society (ATS) Journals Online</source><creator>LoBue, Philip A ; Moser, Kathleen S</creator><creatorcontrib>LoBue, Philip A ; Moser, Kathleen S</creatorcontrib><description>Isoniazid is an efficacious treatment for latent tuberculosis. Concerns remain, however, regarding hepatotoxicity associated with this medication. In addition, adherence may be suboptimal because at least 6 months of treatment is required. We extracted information from our latent tuberculosis treatment database to determine adverse effects and treatment completion rates associated with the use of isoniazid at a county tuberculosis clinic. Outcomes were available for 3,788 patients started on isoniazid between 1999 and 2002. Six hundred seventy-two patients (18%) experienced one or more adverse effects, including 10 (0.3%) determined to have isoniazid-associated liver injury. No hospitalizations or deaths occurred in patients experiencing an adverse effect. A higher incidence of adverse effects was associated with increasing age. Sixty-four percent of patients completed at least 6 months of isoniazid. Higher completion rates were associated with younger age, Hispanic ethnicity, and non-U.S. country of birth. Lower completion rates were associated with being homelessness, using excess alcohol, and having experienced an adverse effect. In summary, we conclude that in our clinic population isoniazid is a safe therapy for latent tuberculosis, but its effectiveness is limited by modest completion rates.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><identifier>DOI: 10.1164/rccm.200303-390OC</identifier><identifier>PMID: 12746255</identifier><language>eng</language><publisher>United States: Am Thoracic Soc</publisher><subject>Adolescent ; Adult ; Age Factors ; Aged ; Alcohol use ; Alcoholism - complications ; Antitubercular Agents - adverse effects ; Antitubercular Agents - therapeutic use ; Chemical and Drug Induced Liver Injury ; Country of birth ; Disease control ; Disease prevention ; Emigration and Immigration ; Ethnic Groups ; Ethnicity ; Female ; Hepatitis ; Hispanic Americans ; Hispanic people ; HIV ; Homeless Persons ; Human immunodeficiency virus ; Humans ; Infections ; Isoniazid - administration & dosage ; Isoniazid - therapeutic use ; Liver diseases ; Male ; Middle Aged ; Patient Compliance ; Patients ; Public Health ; Safety ; Treatment Outcome ; Tuberculosis ; Tuberculosis, Pulmonary - prevention & control ; Variables</subject><ispartof>American journal of respiratory and critical care medicine, 2003-08, Vol.168 (4), p.443-447</ispartof><rights>Copyright American Thoracic Society Aug 15, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-73f802e896472c951af0a5d6639ba6c88fa47247f905083bd1df4e9e7078b21a3</citedby><cites>FETCH-LOGICAL-c449t-73f802e896472c951af0a5d6639ba6c88fa47247f905083bd1df4e9e7078b21a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,4026,4027,27928,27929</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12746255$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LoBue, Philip A</creatorcontrib><creatorcontrib>Moser, Kathleen S</creatorcontrib><title>Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic</title><title>American journal of respiratory and critical care medicine</title><addtitle>Am J Respir Crit Care Med</addtitle><description>Isoniazid is an efficacious treatment for latent tuberculosis. Concerns remain, however, regarding hepatotoxicity associated with this medication. In addition, adherence may be suboptimal because at least 6 months of treatment is required. We extracted information from our latent tuberculosis treatment database to determine adverse effects and treatment completion rates associated with the use of isoniazid at a county tuberculosis clinic. Outcomes were available for 3,788 patients started on isoniazid between 1999 and 2002. Six hundred seventy-two patients (18%) experienced one or more adverse effects, including 10 (0.3%) determined to have isoniazid-associated liver injury. No hospitalizations or deaths occurred in patients experiencing an adverse effect. A higher incidence of adverse effects was associated with increasing age. Sixty-four percent of patients completed at least 6 months of isoniazid. Higher completion rates were associated with younger age, Hispanic ethnicity, and non-U.S. country of birth. Lower completion rates were associated with being homelessness, using excess alcohol, and having experienced an adverse effect. In summary, we conclude that in our clinic population isoniazid is a safe therapy for latent tuberculosis, but its effectiveness is limited by modest completion rates.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Alcohol use</subject><subject>Alcoholism - complications</subject><subject>Antitubercular Agents - adverse effects</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Chemical and Drug Induced Liver Injury</subject><subject>Country of birth</subject><subject>Disease control</subject><subject>Disease prevention</subject><subject>Emigration and Immigration</subject><subject>Ethnic Groups</subject><subject>Ethnicity</subject><subject>Female</subject><subject>Hepatitis</subject><subject>Hispanic Americans</subject><subject>Hispanic people</subject><subject>HIV</subject><subject>Homeless Persons</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Isoniazid - administration & dosage</subject><subject>Isoniazid - therapeutic use</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient Compliance</subject><subject>Patients</subject><subject>Public Health</subject><subject>Safety</subject><subject>Treatment Outcome</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Pulmonary - prevention & control</subject><subject>Variables</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpFkE1LAzEQhoMotlZ_gBcJ3jxszWyS3c1RitrCQj204C1ks4lN2Y-a7CL66926BU8zMM-8MzwI3QKZAyTs0Wtdz2NCKKERFWS9OENT4JRHTKTkfOhJSiPGxPsEXYWwJwTiDMglmkCcsiTmfIrybTC4tXgV2sapH1di23qcq840Hd70hfG6r9rgAl411ujOtQ12DVb4rS8qp_HSqKrb4UXlGqev0YVVVTA3pzpD25fnzWIZ5evX1eIpj_TwTBel1GYkNplIWBprwUFZoniZJFQUKtFZZtUwYKkVhJOMFiWUlhlhUpJmRQyKztD9mHvw7WdvQif3be-b4aQEIXgCwPkAwQhp34bgjZUH72rlvyUQedQnj_rkqE_-6Rt27k7BfVGb8n_j5GsAHkZg5z52X84bGWpVVQMOUu2PgZBkkknGKP0FJ6540g</recordid><startdate>20030815</startdate><enddate>20030815</enddate><creator>LoBue, Philip A</creator><creator>Moser, Kathleen S</creator><general>Am Thoracic Soc</general><general>American Thoracic Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20030815</creationdate><title>Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic</title><author>LoBue, Philip A ; Moser, Kathleen S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-73f802e896472c951af0a5d6639ba6c88fa47247f905083bd1df4e9e7078b21a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Alcohol use</topic><topic>Alcoholism - complications</topic><topic>Antitubercular Agents - adverse effects</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Chemical and Drug Induced Liver Injury</topic><topic>Country of birth</topic><topic>Disease control</topic><topic>Disease prevention</topic><topic>Emigration and Immigration</topic><topic>Ethnic Groups</topic><topic>Ethnicity</topic><topic>Female</topic><topic>Hepatitis</topic><topic>Hispanic Americans</topic><topic>Hispanic people</topic><topic>HIV</topic><topic>Homeless Persons</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Isoniazid - administration & dosage</topic><topic>Isoniazid - therapeutic use</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient Compliance</topic><topic>Patients</topic><topic>Public Health</topic><topic>Safety</topic><topic>Treatment Outcome</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Pulmonary - prevention & control</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LoBue, Philip A</creatorcontrib><creatorcontrib>Moser, Kathleen S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LoBue, Philip A</au><au>Moser, Kathleen S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><addtitle>Am J Respir Crit Care Med</addtitle><date>2003-08-15</date><risdate>2003</risdate><volume>168</volume><issue>4</issue><spage>443</spage><epage>447</epage><pages>443-447</pages><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>Isoniazid is an efficacious treatment for latent tuberculosis. Concerns remain, however, regarding hepatotoxicity associated with this medication. In addition, adherence may be suboptimal because at least 6 months of treatment is required. We extracted information from our latent tuberculosis treatment database to determine adverse effects and treatment completion rates associated with the use of isoniazid at a county tuberculosis clinic. Outcomes were available for 3,788 patients started on isoniazid between 1999 and 2002. Six hundred seventy-two patients (18%) experienced one or more adverse effects, including 10 (0.3%) determined to have isoniazid-associated liver injury. No hospitalizations or deaths occurred in patients experiencing an adverse effect. A higher incidence of adverse effects was associated with increasing age. Sixty-four percent of patients completed at least 6 months of isoniazid. Higher completion rates were associated with younger age, Hispanic ethnicity, and non-U.S. country of birth. Lower completion rates were associated with being homelessness, using excess alcohol, and having experienced an adverse effect. In summary, we conclude that in our clinic population isoniazid is a safe therapy for latent tuberculosis, but its effectiveness is limited by modest completion rates.</abstract><cop>United States</cop><pub>Am Thoracic Soc</pub><pmid>12746255</pmid><doi>10.1164/rccm.200303-390OC</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1073-449X |
| ispartof | American journal of respiratory and critical care medicine, 2003-08, Vol.168 (4), p.443-447 |
| issn | 1073-449X 1535-4970 |
| language | eng |
| recordid | cdi_proquest_journals_199561155 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete; American Thoracic Society (ATS) Journals Online |
| subjects | Adolescent Adult Age Factors Aged Alcohol use Alcoholism - complications Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use Chemical and Drug Induced Liver Injury Country of birth Disease control Disease prevention Emigration and Immigration Ethnic Groups Ethnicity Female Hepatitis Hispanic Americans Hispanic people HIV Homeless Persons Human immunodeficiency virus Humans Infections Isoniazid - administration & dosage Isoniazid - therapeutic use Liver diseases Male Middle Aged Patient Compliance Patients Public Health Safety Treatment Outcome Tuberculosis Tuberculosis, Pulmonary - prevention & control Variables |
| title | Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T17%3A32%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Isoniazid%20for%20Latent%20Tuberculosis%20Infection%20in%20a%20Public%20Health%20Clinic&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=LoBue,%20Philip%20A&rft.date=2003-08-15&rft.volume=168&rft.issue=4&rft.spage=443&rft.epage=447&rft.pages=443-447&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/10.1164/rccm.200303-390OC&rft_dat=%3Cproquest_cross%3E389399981%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=199561155&rft_id=info:pmid/12746255&rfr_iscdi=true |